| Patient | Ray Charles |
|---|---|
| Date of birth | 1960-09-23 |
| Identifiers | MRN HR-ML009-SYN; SSN (made up) 000-09-5561 |
| Document date | 2026-06-02 |
| Author | Gloria Fenwick, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review of recovery, accessibility, and fall prevention. [S]
Mr. Charles returns three months after his first visit. He has stayed well while touring. He keeps one naloxone spray at home and one in his travel bag, and the people he travels with have been shown how to use it. He has had no opioid or other drug use and no cravings, including on long tours and in hotel rooms, which he names as the times he is most careful. His eyes have been comfortable. He has had no falls; in hotels he is shown around each new room on arrival and keeps his belongings in fixed places. He has started working on a plan for any future pain with Dr. Fenwick. [S]
| Element | Detail |
|---|---|
| Recovery | No use and no cravings; aware of travel as a time to be careful |
| Naloxone | At home and in his travel bag; travel staff shown how to use it |
| Eyes | Comfortable |
| Falls | None; spoken orientation to each new hotel room |
| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No eye pain, redness, or discharge |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of suicide or self-harm |
| Musculoskeletal | Negative | No falls or pain |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response, and call 911 | Nasal route | 2026-03-03 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-02 | Body height | 178 | cm | S |
| 2026-06-02 | Body weight | 79.8 | kg | S |
| 2026-06-02 | Body mass index (BMI) [Ratio] | 25.2 | kg/m2 | S |
| 2026-06-02 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-06-02 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-02 | Heart rate | 68 | /min | S |
| 2026-06-02 | Respiratory rate | 14 | /min | S |
| 2026-06-02 | Body temperature | 36.7 | Cel | S |
| 2026-06-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 2026-06-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert and engaged; each step of the examination described before it was done |
| Eyes | No light perception; lids and ocular surfaces quiet |
| Gait | Steady, walking independently after a spoken orientation to the room |
| Psychiatric | Euthymic; no signs of intoxication or withdrawal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Blindness of both eyes since childhood, no light perception; cause never diagnosed | active | confirmed | H54.0X55 | S — Synthetic modern coding of the documented childhood blindness; category 5 (no light perception) is a synthetic grading of what the sources call blindness. |
| Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatment | active | confirmed | F11.21 | S — Synthetic modern coding of the publicly admitted heroin addiction and his documented recovery; listed as an active problem because it is managed at every visit, with remission carried by the code. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Eye comfort and ocular surface check: pain, redness, discharge | Every visit | Completed today | No pain, redness, or discharge |
| Examination | Tonometry (eye pressure) | Every glaucoma visit; for blind eyes, only if pain or redness | Not indicated | Painless blind eyes, as advised by ophthalmology |
| Examination | Comprehensive eye examination | Yearly for blind eyes, or with symptoms | Up to date | Ophthalmology examination two months ago |
| Survey | Depression screen (PHQ-9) | At intake, at six months, and yearly | Up to date | PHQ-9 2 three months ago; mood good; next at six months |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline still saved in his phone |
| Self-management | Recovery check: any return to use, cravings, triggers, and supports | Every visit | Completed today | No return to use and no cravings; touring and hotel stays named as times to be careful, with a plan to call a friend if cravings come |
| Medication safety | Naloxone at home and when traveling | At intake; check expiry at each visit | Completed today | In date, at home and in his travel bag; travel staff shown how to use it |
| Survey | Drug-use screen (DAST-10) | Yearly | Up to date | DAST-10 0 three months ago |
| Survey | Alcohol screen (AUDIT-C) | Yearly | Up to date | AUDIT-C 2 three months ago |
| Laboratory | Hepatitis C, hepatitis B, and HIV testing | At entry to care for a person with a substance use disorder | Due | Planned for the annual wellness visit, as recorded at the four-week visit |
| Self-management | Written plan for any future acute pain or surgery | Before any planned procedure, and once in remission | Due | Drafted today; to be finished at the six-month visit |
| Self-management | Accessible documents and communication | Every visit | Completed today | Visit summaries continue as accessible electronic documents |
| Medication safety | Medicine labeling in braille or audio | With every new prescription | Up to date | No new prescriptions |
| Examination | CDC STEADI fall-risk screen | Every visit from age 65 | Completed today | No falls; steady gait |
| Self-management | Advance care planning | Yearly from age 65 | Due | At the annual wellness visit |
Goal progress:
Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Primary Open-Angle Glaucoma Preferred Practice Pattern (2025); Vision Rehabilitation Preferred Practice Pattern (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, glaucoma and depression, bipolar, and mood disorders monographs (2026)
Follow-up: Six-month review with the PHQ-9 and the finished pain plan. Next scheduled visit 2026-09-01: six-month review with depression screening and a plan for any future pain. [S]